

VPA22664/137/003

FiprocLEAR Combo 268 mg / 241.2 mg spot-on solution for large dogs

Variation	Summary	Date
Vet - B22	VNRA - Vet - B22 - - Vet - B22 - Change to importer, batch control arrangements and quality testing (replacement or addition of a site) for a finished product	22/10/25
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	19/07/23
Vet - F.I.d.1 c)	VRA-R - Vet - F.I.d.1 c) - c) Extension or introduction of a re-test period/storage period supported by real time data - F.I.d.1 c) Quality Changes - Active Substance - Stability -Change in the re-test period/storage period of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - Extension or introduction of a re-test period/storage period supported by real time data	04/11/22
Vet - F.I.a.1 z)	VRA-R - Vet - F.I.a.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.I.a.1 z) - Quality Changes - Active Substance - Manufacture - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	04/11/22